Browse by Poster Presenter

Schedule at a Glance

Icon Legend

This session is not in your schedule.

This session is in your schedule. Click again to remove it.

Browse by Poster Presenter

Type here to filter the list

G
Güler, Sinan E.

Department of Medicine III, University Hospital, LMU Munich, Munich, Germany
(P 410) PHASE I STUDY OF THE001 (DPPG2-TSL-DOX) COMBINED WITH REGIONAL HYPERTHERMIA IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOFT TISSUE SARCOMA
Sinan E. Güler
Favorite
Gónzalez, María Lucila

Instituto Nacional del Cáncer
(P 192) CURRENT SCENARIO OF SARCOMA CLINICAL TRIALS IN SOUTH AMERICA: A REPORT BY THE LACOG SARCOMA GROUP
María Lucila Gónzalez
Favorite
(P 216) SARCOMA CARE PATHWAYS AND MULTIDISCIPLINARY TUMOR BOARDS IN LATIN AMERICA: AN INTERNATIONAL SURVEY BY THE LACOG SARCOMA GROUP
María Lucila Gónzalez
Favorite
(P 217) SARCOMA DRUG APPROVALS IN LATIN AMERICA COMPARED TO THE FDA AND EMA: AN ANALYSIS BY THE LACOG SARCOMA GROUP
María Lucila Gónzalez
Favorite
(P 219) SOCIAL MEDIA USE AMONG MEDICAL PROFESSIONALS THAT TREAT PATIENTS WITH SARCOMA IN LATIN AMERICA: RESULTS OF AN INTERNATIONAL SURVEY BY THE LACOG SARCOMA GROUP
María Lucila Gónzalez
Favorite
Gains, Jennifer

University College Hospitals London
(P 60) DIAGNOSIS AND MANAGEMENT OF PAEDIATRIC EWING SARCOMA PATIENTS IN ENGLAND 2014-2017: A COMPARISON OF NATIONAL DATA WITH THE EURO-EWING 2012 CLINICAL TRIAL
Jennifer Gains
Favorite
Galoaa, Bishoy

Massachusetts General Hospital
(P 100) ADVANCING PROGNOSTICS IN ONCOLOGY: MACHINE LEARNING MODELS FOR PREDICTING 2-YEAR AND 5-YEAR SURVIVAL RATES IN PATIENTS WITH UNDIFFERENTIATED PLEOMORPHIC SARCOMA
Bishoy Galoaa
Favorite
Galoian, Karina

University o f Miami, Miller School of Medicine, Department of Orthopedic Surgery
(P 55) CHONDROSARCOMA PATIENT CHARACTERISTICS AND DIAGNOSTIC AND TREATMENT PATHWAYS: GLOBAL CHONDROSARCOMA PATIENT REGISTRY
Karina Galoian
Favorite
Gambarotti, Marco

Department of Pathology, IRCCS, Istituto Ortopedico Rizzoli
(P 77) MULTI-PARAMETRICAL PROFILING OF CHONDROSARCOMA
Marco Gambarotti
Favorite
(P 86) RESPONSE TO MIFAMURTIDE AND TUMOR MICROENVIRONMENT: A DECONVOLUTION NANOSTRING ANALYSIS IN LOCALIZED OSTEOSARCOMA PATIENTS TREATED WITHIN THE ISG/OS2 CLINICAL TRIAL
Marco Gambarotti
Favorite
Ganapathi, Shireen

Seattle Children's Research Institute
(P 330) EFFICACY OF NON-CARDIOTOXIC ANTHRACYCLINES IN EWING SARCOMA
Shireen Ganapathi
Favorite
Ganjoo, Kristen

Stanford Comprehensive Cancer Center
(P 143) EARLY ASSESSMENT OF DISEASE RESPONSE TO IMMUNOTHERAPY VIA CIRCULATING TUMOR DNA IN ADVANCED SOFT TISSUE SARCOMAS
Kristen Ganjoo
Favorite
(P 161) UTILITY OF CTDNA MONITORING IN THE ADJUVANT AND METASTATIC SETTING IN SOFT TISSUE SARCOMA
Kristen Ganjoo
Favorite
(P 202) IMPACT OF AFAMI-CEL ON THE HEALTH STATE OF PATIENTS WITH ADVANCED SYNOVIAL SARCOMA OR MYXOID/ROUND CELL LIPOSARCOMA: COHORT 1 OF SPEARHEAD-1
Kristen Ganjoo
Favorite
(P 427) MULTI-OMIC AND MULTI-REGION PROFILING OF DESMOID TUMORS REVEALS INTRA- AND INTER-TUMOR HETEROGENEITY
Kristen Ganjoo
Favorite
Gantzer, Justine

ICANS
(P 125) CHARACTERISTICS, MANAGEMENT AND SURVIVAL OF N=7314 LIPOSARCOMAS FROM THE NATIONWIDE NETSARC REGISTRY IN FRANCE SINCE 2010
Justine Gantzer
Favorite
García Maroto, Roberto

Hospital Clinico san Carlos
(P 208) PSYCOLOGICAL ASSESSMENT IN A SAMPLE OF PATIENTS AT HOSPITAL CLÍNICO SAN CARLOS (MADRID), SARCOMA NATIONAL REFERRAL CENTRE IN SPAIN. HIGHLIGTHING THE NEED OF A GLOBAL STANDARIZED PSYCHOLOGICAL APPROACH
Roberto García Maroto
Favorite
Garcia Garcia-Esquinas, Marta

Hospital Clinico san Carlos
(P 208) PSYCOLOGICAL ASSESSMENT IN A SAMPLE OF PATIENTS AT HOSPITAL CLÍNICO SAN CARLOS (MADRID), SARCOMA NATIONAL REFERRAL CENTRE IN SPAIN. HIGHLIGTHING THE NEED OF A GLOBAL STANDARIZED PSYCHOLOGICAL APPROACH
Marta Garcia Garcia-Esquinas
Favorite
Garcia, Jacob

Umoja Biopharma
(P 226) EARLY EXPERIENCE ON ENLIGHTEN-01: A PHASE 1 STUDY OF BISPECIFIC ADAPTER MOLECULE- CONTROLLED FOLATE RECEPTOR CAR T-CELL THERAPY FOR RELAPSED/REFRACTORY OSTEOSARCOMA
Jacob Garcia
Favorite
Garcia, Josep

Inhibrx Biosciences, Inc.
(P 95) THE TETRAVALENT DEATH RECEPTOR 5 AGONIST OZEKIBART (INBRX-109) IN PATIENTS WITH CHONDROSARCOMA: UPDATED RESULTS FROM A PHASE 1 STUDY
Josep Garcia
Favorite
Garcia, Nicolas

Seattle Children's Research Institute
(P 330) EFFICACY OF NON-CARDIOTOXIC ANTHRACYCLINES IN EWING SARCOMA
Nicolas Garcia
Favorite
Garcia-Ortega, Dorian

National Cancer Institute Mexico
(P 213) REGIONAL KNOWLEDGE TRANSLATION IN RETROPERITONEAL SARCOMAS: IMPACT OF AN EDUCATIONAL WEBINAR SERIES BY THE MEXICAN SARCOMA GROUP
Dorian Garcia-Ortega
Favorite
(P 367) AGE AS A PROGNOSTIC FACTOR IN RETROPERITONEAL SARCOMA: A MULTICENTER LATIN AMERICAN STUDY
Dorian Garcia-Ortega
Favorite
(P 374) FACTORS ASSOCIATED WITH RECURRENCE IN DEDIFFERENTIATED RETROPERITONEAL LIPOSARCOMA: ANALYSIS AT A REFERENCE CENTER
Dorian Garcia-Ortega
Favorite
Gardner, Rebecca

St. Jude Children's Research Hospital
(P 226) EARLY EXPERIENCE ON ENLIGHTEN-01: A PHASE 1 STUDY OF BISPECIFIC ADAPTER MOLECULE- CONTROLLED FOLATE RECEPTOR CAR T-CELL THERAPY FOR RELAPSED/REFRACTORY OSTEOSARCOMA
Rebecca Gardner
Favorite
Garland-Kledzik, Mary

West Virginia University
(P 342) THE ROLE OF MYELOPEROXIDASE IN SARCOMA TREATMENT
Mary Garland-Kledzik
Favorite
Garofalo, Serena

Fondazione Policlinico Campus Bio-Medico of Rome
(P 178) PREDICTION OF PRIMARY IMATINIB-REFRACTORY PATIENTS WITH LOCALLY ADVANCED OR METASTATIC GASTROINTESTINAL STROMAL TUMOR (GIST) USING RADIOMICS AND ARTIFICIAL INTELLIGENCE (AI)
Serena Garofalo
Favorite
Gartner, Jared

Surgery Branch, NCI, NIH
(P 231) IDENTIFICATION OF NEOANTIGEN FROM PECOMA-LIKE NEOPLASM PROVIDES RATIONALE FOR TREATMENT WITH CELLULAR THERAPY
Jared Gartner
Favorite
Gartrell, Jessica

St. Jude Children’s Research Hospital
(P 288) ANGIOA: A SAFETY AND TOLERABILITY STUDY OF TRIPLE ANTI-ANGIOGENIC THERAPY COMBINED WITH PD-L1 BLOCKADE IN PEDIATRIC, ADOLESCENT AND YOUNG ADULT RECURRENT/REFRACTORY SOLID TUMORS
Jessica Gartrell
Favorite
Garzia, Livia

McGill University and RI-MUHC
(P 69) H3.3G34W ONCOHISTONE IN OSTEOSARCOMA
Livia Garzia
Favorite
(P 78) NOVEL EPIGENETIC MECHANISMS DRIVE AGGRESSIVE OSTEOSARCOMA PATHOGENESIS AND DRUG RESISTANCE
Livia Garzia
Favorite
Gasho, Jordan

Keck School of Medicine of the University of Southern California
(P 197) EVALUATION OF REVIEWS OF ORTHOPAEDIC ONCOLOGISTS ON INSTITUITIONAL AND PATIENT REVIEW WEBSITES
Jordan Gasho
Favorite
Gaspar, Nathalie

Gustave Roussy Cancer Campus
(P 49) A WORKING GROUP FOR THE DEVELOPMENT OF A CLINICAL FRAMEWORK THAT STRATIFIES OSTEOSARCOMA PATIENTS USING BIOMARKERS OF CLINICAL RISK AND BIOLOGY
Nathalie Gaspar
Favorite
(P 53) CHARACTERIZING THE SPATIAL TRANSCRIPTOMIC LANDSCAPE OF OSTEOSARCOMA FROM DIAGNOSIS TO RELAPSE
Nathalie Gaspar
Favorite
Gaspar, Nathalie

Gustave Roussy
(P 82) PLASMA CIRCULATING PROTEOMIC MARKERS ARE ASSOCIATED WITH METASTATIC SPREAD AND OUTCOME IN OSTEOSARCOMA
Nathalie Gaspar
Favorite
Gaulier, Patrick

University of Michigan
(P 45) UTILIZATION OF MENTAL HEALTH AND SUPPORTIVE CARE RESOURCES AMONG PATIENTS WITH DESMOID TUMORS
Patrick Gaulier
Favorite
Gaunt, Piers

University of Birmingham
(P 60) DIAGNOSIS AND MANAGEMENT OF PAEDIATRIC EWING SARCOMA PATIENTS IN ENGLAND 2014-2017: A COMPARISON OF NATIONAL DATA WITH THE EURO-EWING 2012 CLINICAL TRIAL
Piers Gaunt
Favorite
Gazendam, Aaron

University of Toronto
(P 71) LIMB-SALVAGE SURGERY AFTER UNPLANNED SURGERY FOR EXTREMITY BONE SARCOMAS: 30-YEAR EXPERIENCE AT A TERTIARY REFERRAL CENTER
Aaron Gazendam
Favorite
(P 281) THE UTILITY OF INTRAOPERATIVE MARROW MARGIN FROZEN SECTION IN EXTREMITY BONE SARCOMA RESECTION
Aaron Gazendam
Favorite
Geary, Elizabeth

University of Iowa
(P 14) HDAC INHIBITORS DOWNREGULATE THE EXPRESSION LEVELS OF THE MINI-CHROMOSOME MAINTENANCE PROTEINS, AND INHIBIT DNA REPLICATION, IN EWING SARCOMA CELLS
Elizabeth Geary
Favorite
ge, 赛

Peking University Cancer Hospital
(P 180) TUMOR VASCULAR SIGN IN THE RESPONSE ASSESSMENT OF GASTROINTESTINAL STROMAL TUMOR TREATED WITH RIPRETINIB: A MULTICENTER STUDY
赛 ge
Favorite
Geiger, Erik

University of Miami, Sylvester Comprehensive Cancer Center
(P 358) RADIOMIC EVALUATION OF MRIS IN PATIENTS WITH SOFT TISSUE SARCOMA TREATED WITH STEREOTACTIC BOSY RADIATION THERAPY
Erik Geiger
Favorite
Gelderblom, Hans

Leiden University Medical Center
(P 37) HEALTH-RELATED QUALITY OF LIFE FROM A PHASE 4 STUDY TO EVALUATE DISCONTINUATION AND RECHALLENGE OF PEXIDARTINIB IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR PREVIOUSLY TREATED WITH PEXIDARTINIB
Hans Gelderblom
Favorite
(P 42) RANKL-INHIBITION FOR GIANT CELL LESIONS OF THE JAW: A RETROSPECTIVE COHORT ANALYSIS
Hans Gelderblom
Favorite
(P 43) SAFETY AND EFFICACY WITH VIMSELTINIB IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR WHO RECEIVED NO PRIOR ANTI-COLONY-STIMULATING FACTOR 1 THERAPY: ONGOING PHASE 2 STUDY
Hans Gelderblom
Favorite
(P 181) UPDATED OVERALL SURVIVAL WITH RIPRETINIB VS SUNITINIB IN PATIENTS WITH SECOND-LINE ADVANCED GASTROINTESTINAL STROMAL TUMOR AND KIT EXON 11+17/18 MUTATIONS: CIRCULATING TUMOR DNA ANALYSIS FROM INTRIGUE
Hans Gelderblom
Favorite
(P 319) THE SURVIVAL DISPARITY BETWEEN CHILDREN AND ADOLESCENTS & YOUNG ADULTS WITH EWING SARCOMA IN THE NETHERLANDS DID NOT CHANGE SINCE THE 1990S DESPITE IMPROVED SURVIVAL: A POPULATION-BASED STUDY
Hans Gelderblom
Favorite
(P 349) LONG-TERM SURVIVAL OF PARTICIPANTS IN THE PASART-1 AND PASART-2 TRIALS OF NEO-ADJUVANT PAZOPANIB AND RADIOTHERAPY IN SOFT TISSUE SARCOMA
Hans Gelderblom
Favorite
(P 401) A PHASE 3 MULTI-CENTER, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL TO ASSESS THE EFFICACY AND SAFETY OF EMACTUZUMAB IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR (TANGENT)
Hans Gelderblom
Favorite
Geller, David

Montefiore Medical Center - Orthopaedic Oncology
(P 147) INVESTIGATING THE POTENTIAL OF EXTRACELLULAR VESICLE BIOMARKERS IN SYNOVIAL SARCOMA DETECTION
David Geller
Favorite
(P 156) PROFILING SYNOVIAL SARCOMA EXTRACELLULAR VESICLES FOR DIAGNOSTIC RNA BIOMARKERS
David Geller
Favorite
Geoerger, Birgit

Gustave Roussy Cancer Center, Department of Pediatric and Adolescent Oncology, Université Paris-Saclay, INSERM U1015, Villejuif, France
(P 53) CHARACTERIZING THE SPATIAL TRANSCRIPTOMIC LANDSCAPE OF OSTEOSARCOMA FROM DIAGNOSIS TO RELAPSE
Birgit Geoerger
Favorite
Geoerger, Birgit

Gustave Roussy
(P 82) PLASMA CIRCULATING PROTEOMIC MARKERS ARE ASSOCIATED WITH METASTATIC SPREAD AND OUTCOME IN OSTEOSARCOMA
Birgit Geoerger
Favorite
George, Suzanne

Dana-Farber Cancer Institute
(P 181) UPDATED OVERALL SURVIVAL WITH RIPRETINIB VS SUNITINIB IN PATIENTS WITH SECOND-LINE ADVANCED GASTROINTESTINAL STROMAL TUMOR AND KIT EXON 11+17/18 MUTATIONS: CIRCULATING TUMOR DNA ANALYSIS FROM INTRIGUE
Suzanne George
Favorite
(P 195) ENHANCING PARTICIPANT ENGAGEMENT IN A NOVEL PATIENT-PARTNERED CANCER GENOMICS RESEARCH EFFORT FOR RARE AND AGGRESSIVE SARCOMAS
Suzanne George
Favorite
(P 402) A PILOT STUDY OF BTX-A51 IN PATIENTS WITH METASTATIC AND/OR RECURRENT LIPOSARCOMAS CHARACTERIZED BY MDM2 AMPLIFICATIONS
Suzanne George
Favorite
Gerber, David

University of Texas Southwestern Medical Center
(P 417) VITAS: ATEZOLIZUMAB IN COMBINATION WITH CHEMOTHERAPY FOR PEDIATRIC RELAPSED/REFRACTORY SOLID TUMORS: AN OPEN-LABEL, PHASE I/II, SINGLE-ARM, MULTI-CENTER TRIAL IN PROGRESS
David Gerber
Favorite
Gerrand, Craig

Royal National Orthopaedic Hospital, NHS England
(P 60) DIAGNOSIS AND MANAGEMENT OF PAEDIATRIC EWING SARCOMA PATIENTS IN ENGLAND 2014-2017: A COMPARISON OF NATIONAL DATA WITH THE EURO-EWING 2012 CLINICAL TRIAL
Craig Gerrand
Favorite
Gervais, Mai-Kim

Hôpital Maisonneuve Rosemont
(P 321) WHOLE ABDOMINAL RADIOTHERAPY IN CHILDREN AND YOUNG ADULTS WITH SARCOMA: A CANADIAN SARCOMA AND CLINICAL COLLABORATION (CANSARCC) STUDY
Mai-Kim Gervais
Favorite
Gervais, Thomas

µFO Lab, Polytechnique Montréal, Montréal, Canada, Centre de recherche du Centre hospitalier de l’Université de Montréal (CRCHUM), Montréal, Canada, Institut du Cancer de Montréal (ICM), Montréal, Canada
(P 326) CELL-FREE DNA AS A BIOMARKER FOR CELL DEATH AND TREATMENT RESPONSE IN ON-CHIP THREE-DIMENSIONAL SARCOMA TUMOR MODELS
Thomas Gervais
Favorite
Ge, Xinyi

University of Utah
(P 332) ENHANCING THERAPEUTIC EFFICACY IN SYNOVIAL SARCOMA BY TARGETING P53-MDM2 AXIS AND HDAC PATHWAYS
Xinyi Ge
Favorite
(P 343) TLE1 DISRUPTION DOES NOT IMPEDE SYNOVIAL SARCOMAGENESIS
Xinyi Ge
Favorite
Ghani, Saeed

Helios Klinikum Berlin-Buch and Medical School Berlin
(P 410) PHASE I STUDY OF THE001 (DPPG2-TSL-DOX) COMBINED WITH REGIONAL HYPERTHERMIA IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOFT TISSUE SARCOMA
Saeed Ghani
Favorite
Ghini, Virginia

Irst - Meldola
(P 144) EXPLORATORY ANALYSIS OF 68GA-FAPI-46 PET-CT IN SOFT TISSUE SARCOMA
Virginia Ghini
Favorite
Giacalone, Joseph

Atlantic Health System
(P 405) LIPOSOMAL BUPIVACAINE DOESN'T REDUCE NARCOTIC USE OR PAIN SCORES COMPARED TO A MULTIDRUG COCKTAIL FOLLOWING SOFT TISSUE TUMOR REMOVAL: PRELIM RESULTS OF A PROSPECTIVE, RANDOMIZED DOUBLE-BLINDED STUDY
Joseph Giacalone
Favorite
Giani, Claudia

Fondazione IRCCS Istituto Nazionale dei Tumori
(P 110) INTERNATIONAL MULTICENTER RETROSPECTIVE STUDY OF PLEOMORPHIC RHABDOMYOSARCOMA (P-RMS), A PUSH PLATFORM STUDY: OUTCOME OF LOCALIZED AND ADVANCED DISEASE
Claudia Giani
Favorite
(P 111) INTERNATIONAL MULTICENTER RETROSPECTIVE STUDY OF SPINDLE CELL/ SCLEROSING RHABDOMYOSARCOMA (S-RMS), A PUSH PLATFORM STUDY: OUTCOME OF LOCALIZED AND ADVANCED DISEASE
Claudia Giani
Favorite
(P 429) PATIENTS WITH ADVANCED EPITHELIOID HEMANGIOENDOTHELIOMA TREATED WITH SIROLIMUS: OUTCOME FOLLOWING SIROLIMUS DISCONTINUATION.
Claudia Giani
Favorite
Giannikou, Krinio

Children's Hospital Los Angeles
(P 88) SPATIAL TRANSCRIPTOMICS OF EWING SARCOMA: EVOLUTION OF TUMOR MICROENVIRONMENT ASSOCIATED EXTRACELLULAR MATRIX FROM LOCALIZED TO METASTASIS-ASSOCIATED PRIMARY TUMORS
Krinio Giannikou
Favorite
Gildea, Carolynn

National Disease Registration Service, NHS England
(P 60) DIAGNOSIS AND MANAGEMENT OF PAEDIATRIC EWING SARCOMA PATIENTS IN ENGLAND 2014-2017: A COMPARISON OF NATIONAL DATA WITH THE EURO-EWING 2012 CLINICAL TRIAL
Carolynn Gildea
Favorite
Gill, Gurveer

University of Calgary
(P 289) APPLICATION AND ANALYSIS OF SPATIAL TRANSCRIPTOMIC PROFILING TO CLINICAL ALVEOLAR SOFT PART SARCOMA SAMPLES TO UNDERSTAND IMMUNOTHERAPY-RELEVANT VARIABLES
Gurveer Gill
Favorite
Gill, Jaya

Precision NextGen Oncology and Research Center
(P 140) CIRCULATING TUMOR DNA AS A TOOL OF SURVEILLANCE AND EARLY INDICATOR OF RELAPSE IN SARCOMA PATIENTS
Jaya Gill
Favorite
Gingrich, Alicia

University of Nevada
(P 233) IMMUNE CLASSES OF LEIOMYOSARCOMA DRIVEN BY B CELL INFILTRATE AND CTLA4 EXPRESSION
Alicia Gingrich
Favorite
Giordano, Giorgia

Candiolo Cancer Institute IRCCS FPO
(P 345) TRANSCRIPTOMIC AND PHENOTYPIC CHARACTERIZATION OF AN IMMUNOCOMPETENT LEIOMYOSARCOMA MOUSE MODEL.
Giorgia Giordano
Favorite
Giordano, Laura

Humanitas Research Hospital
(P 431) REAL-WORLD EXPERIENCE OF EFFICACY AND TOLERABILITY OF CONTINUOS INFUSION IFOSFAMIDE AMONG ADVANCED SOFT TISSUE AND BONE SARCOMAS PATIENTS: A SINGLE CENTRE RETROSPECTIVE COHORT.
Laura Giordano
Favorite
Giordano, Marco

Ospedale Pediatrico Bambino Gesù
(P 311) QUANTIFICATION OF TUMOUR-INFILTRATING IMMUNE CELLS THROUGH DECONVOLUTION OF DNA METHYLATION DATA IN EWING SARCOMAS
Marco Giordano
Favorite
Giovannoni, Isabella

Ospedale Pediatrico Bambino Gesù
(P 311) QUANTIFICATION OF TUMOUR-INFILTRATING IMMUNE CELLS THROUGH DECONVOLUTION OF DNA METHYLATION DATA IN EWING SARCOMAS
Isabella Giovannoni
Favorite
Girgis, Andrew

Massachusetts General Hospital
(P 100) ADVANCING PROGNOSTICS IN ONCOLOGY: MACHINE LEARNING MODELS FOR PREDICTING 2-YEAR AND 5-YEAR SURVIVAL RATES IN PATIENTS WITH UNDIFFERENTIATED PLEOMORPHIC SARCOMA
Andrew Girgis
Favorite
Gitelis, Steven

Rush University Medical Center
(P 31) CLINICAL CHALLENGES AND EVOLVING TREATMENT STRATEGIES IN DESMOID FIBROMATOSIS: A SINGLE INSTITUTION EXPERIENCE
Steven Gitelis
Favorite
(P 80) OUTCOMES AND MANAGEMENT OF POSITIVE MARGINS IN CHONDROSARCOMA WITH SOFT TISSUE EXTENSION: A CASE SERIES AND REVIEW OF LITERATURE
Steven Gitelis
Favorite
(P 92) THE IMPACT OF CHONDROSARCOMA WITH POSITIVE MARGINS AND EXTRAOSSEOUS EXTENSION ON PATIENT OUTCOMES
Steven Gitelis
Favorite
(P 126) CHARACTERIZING THE TRANSFORMATION AND DIAGNOSIS OF ATYPICAL LIPOMATOUS TUMOR OF THE EXTREMITIES TO DEDIFFERENTIATED LIPOSARCOMA: SINGLE INSTITUTIONAL OUTCOMES
Steven Gitelis
Favorite
(P 270) OPIOID USE IN IMPENDING VERSUS PATHOLOGIC PROXIMAL FEMUR FRACTURES
Steven Gitelis
Favorite
Gladdy, Rebecca

Lunenefeld Tanenbaum, Mount Sinai Hospital, University Health Network, University Of Toronto
(P 159) USING THE TRANSCRIPTIONAL SPECTRUM OF UTERINE SMOOTH MUSCLE TUMORS TO IDENTIFY PROGNOSTIC SIGNATURES FOR ABNORMAL LEIOMYOMAS AND SMOOTH MUSCLE TUMOURS OF UNCERTAIN MALIGNANT POTENTIAL
Rebecca Gladdy
Favorite
(P 329) DEVELOPING ARMS METASTATIC MODELS TO RECAPITULATE THE TUMOR MICROENVIRONMENTS OF THE AXILLA/LYMPH NODE AND LUNGS
Rebecca Gladdy
Favorite
Gladdy, Rebecca

Department of Surgery, Mount Sinai Hospital; Department of Surgery, University of Toronto; Department of Surgical Oncology, Princess Margaret Cancer Centre, University of Toronto; CanSaRCC, Princess Margaret Cancer Centre, Toronto
(P 376) IMPACT OF SITE OF ORIGIN ON THE PROGNOSIS OF PATIENTS WITH PRIMARY RESECTABLE NON-UTERINE ABDOMINAL LEIOMYOSARCOMA
Rebecca Gladdy
Favorite
Gladdy, Rebecca

Lunenefeld Tanenbaum, Mount Sinai Hospital, University Health Network, University Of Toronto
(P 433) TUMOR HYPOXIA AND THE RISK OF METASTASIS IN HIGH-RISK LOCALIZED UPS/MFS
Rebecca Gladdy
Favorite
Glade Bender, Julia

Memorial Sloan Kettering Cancer Center
(P 50) ANALYSIS OF CLINICAL FEATURES AND OUTCOMES FOR PATIENTS WITH MULTIFOCAL OSTEOSARCOMA: A REPORT FROM THE CHILDREN'S ONCOLOGY GROUP
Julia Glade Bender
Favorite
Glod, John

Center for Cancer Research/National Cancer Institute
(P 163) CHARACTERIZATION OF INTRAHEPATIC RECURRENCE FOLLOWING LIVER-DIRECTED SURGERY IN PATIENTS WITH METASTATIC SDH-DEFICIENT GASTROINTESTINAL STROMAL TUMOR (GIST): RISE AND STABILIZATION OF THE GISTLETS
John Glod
Favorite
Goh, Megan H.

Massachusetts General Hospital
(P 107) DOES THE USE OF ADJUVANT CHEMOTHERAPY IN LOCALIZED, RESECTABLE SOFT TISSUE SARCOMA LEAD TO BETTER SURVIVAL OUTCOMES? - A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS
Megan H. Goh
Favorite
Gokgoz, Nalan

The Lunenfeld-Tanenbaum Research Institute
(P 225) DETERMINING THE CONTRIBUTIONS OF STAT1 AND THE Y701 PHOSPHORYLATION TO THE UPS ANTI-TUMOR MICROENVIRONMENT
Nalan Gokgoz
Favorite
Gokgoz, Nalan

Lunenfeld Research Institute
(P 238) INTRA-TUMORAL DC-LAMP EXPRESSION IS ASSOCIATED WITH PROGNOSIS IN SOFT TISSUE SARCOMA
Nalan Gokgoz
Favorite
Golden, Lexi

University of Michigan
(P 131) HETEROGENEITY OF THE IMMUNE MICROENVIRONMENT AND IMMUNOTHERAPY RESPONSE IN A DEDIFFERENTIATED LIPOSARCOMA MOUSE MODEL
Lexi Golden
Favorite
(P 341) THE EFFECTS OF ULTRASOUND-GUIDED HISTOTRIPSY ON SOFT TISSUE SARCOMA
Lexi Golden
Favorite
Goldsby, Robert

UCSF Benioff Children's Hospital Oakland
(P 50) ANALYSIS OF CLINICAL FEATURES AND OUTCOMES FOR PATIENTS WITH MULTIFOCAL OSTEOSARCOMA: A REPORT FROM THE CHILDREN'S ONCOLOGY GROUP
Robert Goldsby
Favorite
Golik, Paweł

Institute of Genetics and Biotechnology, Faculty of Biology, University of Warsaw, Warsaw, Poland & Institute of Biochemistry and Biophysics Polish Academy of Science, Warsaw, Poland
(P 77) MULTI-PARAMETRICAL PROFILING OF CHONDROSARCOMA
Paweł Golik
Favorite
González Woge, Miguel Angel

Centro Médico ABC
(P 213) REGIONAL KNOWLEDGE TRANSLATION IN RETROPERITONEAL SARCOMAS: IMPACT OF AN EDUCATIONAL WEBINAR SERIES BY THE MEXICAN SARCOMA GROUP
Miguel Angel González Woge
Favorite
Gonzalez-Billalabeitia, Enrique

HU Doce de Octubre
(P 234) IMMUNOSARC II MASTER TRIAL (PHASE II OF SUNITINIB AND NIVOLUMAB): RESULTS FROM THE CLEAR CELL SARCOMA (CCS) COHORT. A GEIS, ISG, AND UCL STUDY
Enrique Gonzalez-Billalabeitia
Favorite
González, Macarena

Vall d´Hebrón University Hospital, Vall d´Hebrón Institute of Oncology
(P 408) OSTEOMYC: A PHASE 2 PILOT STUDY TO EVALIATE THE SAFETY AND THE ANTITUMOR ACTIVITY OF THE MYC INHIBITOR OMO-103 ADMINISTERED INTRAVENOUSLY IN PATIENTS WITH ADVANCED HIGH GRADE OSTEOSARCOMA
Macarena González
Favorite
Gonzalez, Marcos

Massachusetts General Hospital
(P 63) DOES TUMOR NECROSIS IMPACT PROGNOSIS IN CHONDROBLASTIC AND OSTEOBLASTIC OSTEOSARCOMA? A STUDY FROM A LARGE TERTIARY CARE ACADEMIC CENTER
Marcos Gonzalez
Favorite
(P 100) ADVANCING PROGNOSTICS IN ONCOLOGY: MACHINE LEARNING MODELS FOR PREDICTING 2-YEAR AND 5-YEAR SURVIVAL RATES IN PATIENTS WITH UNDIFFERENTIATED PLEOMORPHIC SARCOMA
Marcos Gonzalez
Favorite
(P 107) DOES THE USE OF ADJUVANT CHEMOTHERAPY IN LOCALIZED, RESECTABLE SOFT TISSUE SARCOMA LEAD TO BETTER SURVIVAL OUTCOMES? - A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS
Marcos Gonzalez
Favorite
(P 108) FIXATION OF IMPENDING OR PATHOLOGIC FRACTURES DUE TO METASTATIC DISEASE WITH CARBON FIBER INTRAMEDULLARY NAILS-A PROPENSITY-SCORE MATCHED COST ANALYSIS
Marcos Gonzalez
Favorite
(P 284) WOUND VAC TEMPORIZATION AFTER TUMOR RESECTION OF SOFT TISSUE SARCOMAS - A COST ANALYSIS IN A PROPENSITY-SCORE MATCHED POPULATION
Marcos Gonzalez
Favorite
Gonzalez, Ricardo

Moffitt Cancer Center
(P 237) INTRALESIONAL ADMINISTRATION OF TALIMOGENE LAHERPAREPVEC (T-VEC) INDUCES TUMOR REGRESSION IN PATIENTS WITH CUTANEOUS ANGIOSARCOMA
Ricardo Gonzalez
Favorite
Goodman, Mark

UPMC
(P 256) CHARACTERIZING ORTHOPAEDIC ONCOLOGIC POLYTRAUMAS: A COMPARISON OF PATIENTS UNDERGOING OPERATIVE FIXATION OF MULTIPLE LESIONS WITH THOSE WITH SOLITARY LESIONS
Mark Goodman
Favorite
(P 258) COMPARING OUTCOMES FOLLOWING INTRALESIONAL VERSUS WIDE RESECTION PROCEDURES IN THE TREATMENT OF RENAL CELL CARCINOMA BONE METASTASES
Mark Goodman
Favorite
Goodspeed, Andrew

University of Colorado Cancer Center
(P 88) SPATIAL TRANSCRIPTOMICS OF EWING SARCOMA: EVOLUTION OF TUMOR MICROENVIRONMENT ASSOCIATED EXTRACELLULAR MATRIX FROM LOCALIZED TO METASTASIS-ASSOCIATED PRIMARY TUMORS
Andrew Goodspeed
Favorite
Gordon, David

University of Iowa
(P 14) HDAC INHIBITORS DOWNREGULATE THE EXPRESSION LEVELS OF THE MINI-CHROMOSOME MAINTENANCE PROTEINS, AND INHIBIT DNA REPLICATION, IN EWING SARCOMA CELLS
David Gordon
Favorite
Gordon, Erlinda

Sarcoma Oncology Research Center
(P 106) DELTAREX-G, A TUMOR TARGETED CCNG1 INHIBITOR, DEMONSTRATES CLINICAL BENEFIT IN ADVANCED CHEMORESISTANT SARCOMA FOLLOWING FDA CBER AUTHORIZATION FOR USE AS PLATFORM THERAPY WITH FDA APPROVED DRUGS
Erlinda Gordon
Favorite
(P 241) LINNOVATE: A PHASE 1/2 STUDY OF SAFETY/EFFICACY USING LURBINECTEDIN COMBINED WITH IPILUMUMAB AND NIVOLUMAB FOR ADVANCED SOFT TISSUE SARCOMA (NCT05876715)
Erlinda Gordon
Favorite
(P 248) TNT: A PHASE 2 STUDY USING TALIMOGENE LAHERPAREPVEC, NIVOLUMAB, AND TRABECTEDIN FOR ADVANCED LEIOMYOSARCOMA AND LIPOSARCOMA (NCT # 03886311)
Erlinda Gordon
Favorite
(P 250) UPDATE ON GALLANT: A PHASE 2 STUDY USING METRONOMIC GEMCITABINE, DOXORUBICIN AND DOCETAXEL PLUS NIVOLUMAB IN PREVIOUSLY TREATED SARCOMA (NCT04535713)
Erlinda Gordon
Favorite
(P 251) UPDATE ON SAINT: A PHASE 2 STUDY USING TRABECTEDIN (T) IN COMBINATION WITH IPILIMUMAB (L) AND NIVOLUMAB (N) IN PREVIOUSLY TREATED SOFT TISSUE SARCOMA (NCT03138161)
Erlinda Gordon
Favorite
Gordon, Michael

HonorHealth Research Institute
(P 37) HEALTH-RELATED QUALITY OF LIFE FROM A PHASE 4 STUDY TO EVALUATE DISCONTINUATION AND RECHALLENGE OF PEXIDARTINIB IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR PREVIOUSLY TREATED WITH PEXIDARTINIB
Michael Gordon
Favorite
Gorgels, Daniël

Laboratory of Experimental Oncology, KU Leuven
(P 334) EXPANDING THE LANDSCAPE OF PRECLINICAL MODELS OF SYNOVIAL SARCOMA: FROM 2-DIMENSIONS TO 3-DIMENSIONS TO MICE
Daniël Gorgels
Favorite
(P 340) THE DNA MINOR GROOVE BINDING AGENTS ECUBECTEDIN AND PM54 DEMONSTRATE ANTITUMOR ACTIVITY IN PATIENT-DERIVED XENOGRAFT MODELS OF SOFT TISSUE SARCOMA
Daniël Gorgels
Favorite
Gorgone, Pierangelo

Fondazione Policlinico Campus Bio-Medico of Rome
(P 178) PREDICTION OF PRIMARY IMATINIB-REFRACTORY PATIENTS WITH LOCALLY ADVANCED OR METASTATIC GASTROINTESTINAL STROMAL TUMOR (GIST) USING RADIOMICS AND ARTIFICIAL INTELLIGENCE (AI)
Pierangelo Gorgone
Favorite
Gorlick, Richard

The University of Texas MD Anderson Cancer Center
(P 49) A WORKING GROUP FOR THE DEVELOPMENT OF A CLINICAL FRAMEWORK THAT STRATIFIES OSTEOSARCOMA PATIENTS USING BIOMARKERS OF CLINICAL RISK AND BIOLOGY
Richard Gorlick
Favorite
Goryunova, Marina

The Ohio State University
(P 136) TARGETING MIR-138-5P TO TREAT DEDIFFERENTIATED LIPOSARCOMA
Marina Goryunova
Favorite
Gorzeń, Aleksander

Maria Sklodowska-Curie National Research Institute of Oncology
(P 46) A NEED FOR STANDARDIZATION IN TRIAL DESIGN AND DATA REPORTING IN PHASE II TRIALS IN RARE TUMORS. LESSONS LEARNED FROM PHASE II TRIALS IN BONE SARCOMAS
Aleksander Gorzeń
Favorite
Gounder, Mrinal

Memorial Sloan Kettering Cancer Center; Weill Cornell Medical College
(P 121) ACQUIRED CYCLIN D AMPLIFICATION IS A MECHANISM FOR RESISTANCE TO CDK4/6 INHIBITORS IN DEDIFFERENTIATED LIPOSARCOMA
Mrinal Gounder
Favorite
(P 229) EXPRESSION OF TRANSPOSABLE ELEMENTS AND IKZF1 PREDICTS IMMUNE INFILTRATES IN SARCOMAS AND CORRELATES WITH OUTCOMES AFTER IMMUNE CHECKPOINT INHIBITION
Mrinal Gounder
Favorite
Gouveia, Emanuel

Instituto Português de Oncologia de Lisboa
(P 128) DYNAMIC HETEROGENEITY AMONGST LIPOSARCOMAS
Emanuel Gouveia
Favorite
Gozo, Maricel

Deciphera Pharmaceuticals, LLC
(P 403) DCC-3116 IN COMBINATION WITH RIPRETINIB FOR PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMOR: A PHASE 1/2 STUDY
Maricel Gozo
Favorite
Grabowski, Katherine

The Univeristy of Kansas Medical Center General Surgery Residency
(P 36) EARLY REAL-WORLD EXPERIENCE WITH THE USE OF NIROGACESTAT FOR THE TREATMENT OF DESMOID FIBROMATOSIS
Katherine Grabowski
Favorite
Graham, Jess

Yale University
(P 98) A MULTIEPITOPE MRNA VACCINE FOR KAPOSI SARCOMA: AN IMMUNOINFORMATIC APPROACH
Jess Graham
Favorite
Grandhi, Nikhil

Washington University School of Medicine
(P 81) OUTCOMES DATA FOR OSTEOSARCOMA PATIENTS OVER AGE 60
Nikhil Grandhi
Favorite
Graves, Laurie

Department of Pediatrics, Division of Pediatric Hematology/Oncology, Duke University
(P 54) CHONDROBLASTIC OSTEOSARCOMA IS A RISK FACTOR FOR LOCAL RECURRENCE IN PATIENTS WITH SKELETAL OSTEOSARCOMA
Laurie Graves
Favorite
Grbic, Dimitrije

ZRx Outcomes Research Inc.
(P 55) CHONDROSARCOMA PATIENT CHARACTERISTICS AND DIAGNOSTIC AND TREATMENT PATHWAYS: GLOBAL CHONDROSARCOMA PATIENT REGISTRY
Dimitrije Grbic
Favorite
Greco, Francesca

Fondazione IRCCS Istituto Nazionale dei Tumori
(P 429) PATIENTS WITH ADVANCED EPITHELIOID HEMANGIOENDOTHELIOMA TREATED WITH SIROLIMUS: OUTCOME FOLLOWING SIROLIMUS DISCONTINUATION.
Francesca Greco
Favorite
Greco, Gabriella

Fondazione IRCCS Istituto Nazionale dei Tumori
(P 368) AGGRESSIVE PERINEAL ANGIOMYXOMA UNDERGOING SYSTEMIC TREATMENT: AN UPDATED REPORT OF 8-YEARS' EXPERIENCE IN A REFERRAL CENTER
Gabriella Greco
Favorite
Griffin, Anthony

Mount Sinai Hospital- Orthopaedics
(P 71) LIMB-SALVAGE SURGERY AFTER UNPLANNED SURGERY FOR EXTREMITY BONE SARCOMAS: 30-YEAR EXPERIENCE AT A TERTIARY REFERRAL CENTER
Anthony Griffin
Favorite
(P 238) INTRA-TUMORAL DC-LAMP EXPRESSION IS ASSOCIATED WITH PROGNOSIS IN SOFT TISSUE SARCOMA
Anthony Griffin
Favorite
(P 281) THE UTILITY OF INTRAOPERATIVE MARROW MARGIN FROZEN SECTION IN EXTREMITY BONE SARCOMA RESECTION
Anthony Griffin
Favorite
Griffin, Jacob

University of Miami, Sylvester Comprehensive Cancer Center
(P 358) RADIOMIC EVALUATION OF MRIS IN PATIENTS WITH SOFT TISSUE SARCOMA TREATED WITH STEREOTACTIC BOSY RADIATION THERAPY
Jacob Griffin
Favorite
Grignani, Giovanni

Città della Salute e della Scienza di Torino
(P 234) IMMUNOSARC II MASTER TRIAL (PHASE II OF SUNITINIB AND NIVOLUMAB): RESULTS FROM THE CLEAR CELL SARCOMA (CCS) COHORT. A GEIS, ISG, AND UCL STUDY
Giovanni Grignani
Favorite
(P 345) TRANSCRIPTOMIC AND PHENOTYPIC CHARACTERIZATION OF AN IMMUNOCOMPETENT LEIOMYOSARCOMA MOUSE MODEL.
Giovanni Grignani
Favorite
(P 415) TRABECTEDIN PLUS OLAPARIB IN ADVANCED LEIOMYOSARCOMA PROGRESSING AFTER STANDARD TREATMENTS FOR ADVANCED DISEASE: A POOLED ANALYSIS OF TOMAS AND TOMAS2 STUDIES FROM THE ITALIAN SARCOMA GROUP.
Giovanni Grignani
Favorite
Grignol, Valerie

The Ohio State University James Cancer Hospital
(P 378) INGUINAL SARCOMAS - A RETROSPECTIVE ANALYSIS OF DIAGNOSIS, CLINICAL FEATURES, TREATMENT PATTERNS AND OUTCOMES (I-SARC): A STUDY BY TARPSWG
Valerie Grignol
Favorite
(P 390) VARIATIONS IN GLOBAL PATTERNS OF CARE FOR RETROPERITONEAL SARCOMAS - A STUDY BY TARPSWG
Valerie Grignol
Favorite
Grilley-Olson, Juneko

Duke University
(P 47) A PHASE 2 STUDY OF OLAPARIB IN METASTATIC IDH1 AND IDH2 MUTANT CHONDROSARCOMAS
Juneko Grilley-Olson
Favorite
Grimaudo, Maria Susanna

Medical Oncology and Hematology Unit, Humanitas Clinical and Research Center, IRCCS, Rozzano, Milan, 20089, Italy
(P 124) ASSESSMENT OF THE MECHANISMS OF ACTION OF ERIBULIN IN PATIENTS WITH ADVANCED LIPOSARCOMA THROUGH THE EVALUATION OF THE RADIOLOGICAL, FUNCTIONAL AND TISSUE RESPONSE: A MONOCENTRIC PROSPECTIVE STUDY
Maria Susanna Grimaudo
Favorite
Grimaudo, Maria Susanna

Humanitas Research Hospital
(P 155) PRIMARY MESENCHYMAL TUMORS OF THE HEART: A 8-YEARS, SINGLE INSTITUTION EXPERIENCE
Maria Susanna Grimaudo
Favorite
(P 290) ARTIFICIAL INTELLIGENCE-BASED COMPARISON OF ADULT AND ADOLESCENT AND YOUNG ADULTS (AYA) SARCOMAS: A PILOT STUDY
Maria Susanna Grimaudo
Favorite
(P 431) REAL-WORLD EXPERIENCE OF EFFICACY AND TOLERABILITY OF CONTINUOS INFUSION IFOSFAMIDE AMONG ADVANCED SOFT TISSUE AND BONE SARCOMAS PATIENTS: A SINGLE CENTRE RETROSPECTIVE COHORT.
Maria Susanna Grimaudo
Favorite
Grimison, Peter

Chris O'Brien Lifehouse
(P 37) HEALTH-RELATED QUALITY OF LIFE FROM A PHASE 4 STUDY TO EVALUATE DISCONTINUATION AND RECHALLENGE OF PEXIDARTINIB IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR PREVIOUSLY TREATED WITH PEXIDARTINIB
Peter Grimison
Favorite
(P 325) CAN PROTEOMICS PREDICT METASTATIC RELAPSE IN LEIOMYOSARCOMA? DEVELOPMENT OF AN 8 PROTEIN SIGNATURE IN A >350 SAMPLE STUDY INCLUDING A VALIDATION COHORT
Peter Grimison
Favorite
Grobler, Maryke

University of California Santa Cruz, Molecular Cell and Developmental Biology, Genomics Institute
(P 147) INVESTIGATING THE POTENTIAL OF EXTRACELLULAR VESICLE BIOMARKERS IN SYNOVIAL SARCOMA DETECTION
Maryke Grobler
Favorite
(P 156) PROFILING SYNOVIAL SARCOMA EXTRACELLULAR VESICLES FOR DIAGNOSTIC RNA BIOMARKERS
Maryke Grobler
Favorite
Groisberg, Roman

Rutgers Cancer Institute of New Jersey
(P 47) A PHASE 2 STUDY OF OLAPARIB IN METASTATIC IDH1 AND IDH2 MUTANT CHONDROSARCOMAS
Roman Groisberg
Favorite
Gronchi, Alessandro

Fondazione IRCCS Istituto Nazionale dei Tumori
(P 110) INTERNATIONAL MULTICENTER RETROSPECTIVE STUDY OF PLEOMORPHIC RHABDOMYOSARCOMA (P-RMS), A PUSH PLATFORM STUDY: OUTCOME OF LOCALIZED AND ADVANCED DISEASE
Alessandro Gronchi
Favorite
(P 111) INTERNATIONAL MULTICENTER RETROSPECTIVE STUDY OF SPINDLE CELL/ SCLEROSING RHABDOMYOSARCOMA (S-RMS), A PUSH PLATFORM STUDY: OUTCOME OF LOCALIZED AND ADVANCED DISEASE
Alessandro Gronchi
Favorite
(P 137) TARGETING PRIMARY AND SECONDARY ONCOGENIC DRIVERS IN RETROPERITONEAL DEDIFFERENTIATED LIPOSARCOMAS
Alessandro Gronchi
Favorite
(P 160) UTERINE PECOMA: REPORT OF MOLECULAR AND CLINICAL FEATURES IN A SERIES OF PATIENTS TREATED AT A REFERRAL INSTITUTION
Alessandro Gronchi
Favorite
(P 171) GASTROINTESTINAL STROMAL TUMOURS (GISTS) IN NEUROFIBROMATOSIS TYPE (NF1): A SINGLE-CENTER OBSERVATIONAL RETROSPECTIVE STUDY
Alessandro Gronchi
Favorite
(P 368) AGGRESSIVE PERINEAL ANGIOMYXOMA UNDERGOING SYSTEMIC TREATMENT: AN UPDATED REPORT OF 8-YEARS' EXPERIENCE IN A REFERRAL CENTER
Alessandro Gronchi
Favorite
(P 376) IMPACT OF SITE OF ORIGIN ON THE PROGNOSIS OF PATIENTS WITH PRIMARY RESECTABLE NON-UTERINE ABDOMINAL LEIOMYOSARCOMA
Alessandro Gronchi
Favorite
(P 378) INGUINAL SARCOMAS - A RETROSPECTIVE ANALYSIS OF DIAGNOSIS, CLINICAL FEATURES, TREATMENT PATTERNS AND OUTCOMES (I-SARC): A STUDY BY TARPSWG
Alessandro Gronchi
Favorite
(P 390) VARIATIONS IN GLOBAL PATTERNS OF CARE FOR RETROPERITONEAL SARCOMAS - A STUDY BY TARPSWG
Alessandro Gronchi
Favorite
(P 420) CELLULARITY DEGREES IN PRIMARY MYXOID LIPOSARCOMA: ASSOCIATION WITH TUMOR IMMUNE INFILTRATE AND PATIENT OUTCOMES
Alessandro Gronchi
Favorite
(P 429) PATIENTS WITH ADVANCED EPITHELIOID HEMANGIOENDOTHELIOMA TREATED WITH SIROLIMUS: OUTCOME FOLLOWING SIROLIMUS DISCONTINUATION.
Alessandro Gronchi
Favorite
GROSIBERG, ROMAN

Rutgers Cancer Institute of New Jersey
(P 87) SAFETY AND EFFICACY OF OLUTASIDENIB, AN IDH1 MUTANT INHIBITOR, FOR THE TREATMENT OF RECURRENT/ RELAPSED LOCALLY ADVANCED OR METASTATIC IDH1 MUTATED CHONDROSARCOMA
ROMAN GROSIBERG
Favorite
Gross, John

Johns hopkins
(P 152) NOVEL PAX3::MAML3 FUSION IDENTIFIED IN ALVEOLAR RHABDOMYOSARCOMA: USING DNA METHYLATION TO EXPANDE THE GENETIC SPECTRUM OF "FUSION POSITIVE" CASES
John Gross
Favorite
Grossman, Julie

University of Miami
(P 246) THE GENOMIC AND IMMUNE LANDSCAPE OF LIPOSARCOMA AND ITS SUBTYPES
Julie Grossman
Favorite
Groundland, John

Huntsman Cancer Institute
(P 91) THE EFFECT OF CHEMOTHERAPY AND SURGERY TIMING ON MORTALITY IN THE TREATMENT OF UPPER AND LOWER EXTREMITY OSTEOSARCOMA: A DATABASE STUDY
John Groundland
Favorite
Grunn, Adina

Columbia University Irving Medical Center
(P 418) A SYSTEMS BIOLOGY APPROACH FOR CHARACTERIZING TUMOR HETEROGENEITY AND CELL STATE-SPECIFIC THERAPEUTIC VULNERABILITIES FROM SINGLE NUCLEUS RNA-SEQ PROFILING OF DESMOPLASTIC SMALL ROUND CELL TUMORS
Adina Grunn
Favorite
Guadagnolo, B. Ashleigh

The University of Texas MD Anderson Cancer Center
(P 360) TREATMENT OF MALIGNANT PERIPHERAL NERVE SHEATH TUMOR WITH BROMODOMAIN EXTRA TERMINAL INHIBITOR (BETI) IN COMBINATION WITH RADIOTHERAPY
B. Ashleigh Guadagnolo
Favorite
Guardado, Ashley

MD Anderson Cancer Center
(P 130) HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH RESECTABLE RETROPERITONEAL DEDIFFERENTIATED LIPOSARCOMA (DDLPS) TREATED WITH NEOADJUVANT CHECKPOINT BLOCKADE IN A RANDOMIZED PHASE II CLINICAL TRIAL.
Ashley Guardado
Favorite
Guardino, Nicholas

Duke University
(P 15) HISTONE DEACETYLASE-3 PLAYS A ROLE IN THE METASTATIC POTENTIAL OF A SUBPOPULATION OF CELLS IN UNDIFFERENTIATED PLEOMORPHIC SARCOMA
Nicholas Guardino
Favorite
Guerrieri, Ania Naila

Istituto Ortopedico Rizzoli IRCCS, Osteoncology- Bone and Soft Tissue Sarcomas and Innovative Therapies Unit, Bologna, Italy
(P 336) IMPROVEMENT OF PHOTODYNAMIC THERAPY IN SARCOMA: IN VITRO VALIDATION ON OSTEOSARCOMA AND MYXOFIBROSARCOMA
Ania Naila Guerrieri
Favorite
gui, jianping

The First Hospital of Jilin University
(P 119) UPDATED RESULTS OF A SINGLE-ARM,MULTI-CENTER STUDY OF ANLOTINIB COMBINED WITH TORIPALIMAB IN FIRST-LINE TREATMENT OF UNRESECTABLE OR METASTATIC UNDIFFERENTIATED PLEOMORPHIC SARCOMA
jianping gui
Favorite
Guillan, Kristina

Memorial Sloan Kettering Cancer Center
(P 338) PRECLINICAL EFFICACY OF DAN-222, A NOVEL POLYMERIC NANOPARTICLE, IN PEDIATRIC SOLID TUMOR MODELS
Kristina Guillan
Favorite
Guillén, María José

Research Department, PharmaMar S.A.
(P 340) THE DNA MINOR GROOVE BINDING AGENTS ECUBECTEDIN AND PM54 DEMONSTRATE ANTITUMOR ACTIVITY IN PATIENT-DERIVED XENOGRAFT MODELS OF SOFT TISSUE SARCOMA
María José Guillén
Favorite
Gularte Mérida, Rodrigo

Memorial Sloan Kettering Cancer Center
(P 129) ELUCIDATING THE EVOLUTIONARY DYNAMICS OF DDLS LIPOSARCOMA USING SINGLE-CELL SEQUENCING AND MATHEMATICAL LINEAGE TRACING
Rodrigo Gularte Mérida
Favorite
Gulia, Aashish

Tata Memorial Centre
(P 32) CURRENT INDICATIONS OF OPEN SURGERY IN PRIMARY APPENDICULAR/ PELVIC ANEURYSMAL BONE CYSTS
Aashish Gulia
Favorite
(P 306) LONG TERM OUTCOMES OF TYPE BIIIA ROTATIONPLASTY AFTER TOTAL FEMUR EXCISION IN CHILDREN
Aashish Gulia
Favorite
Gundle, Kenneth

Oregon Health & Science University
(P 34) DESMOID TUMOR COHORT CREATION AND CHARACTERISTICS IN THE VETERANS AFFAIRS (VA) NATIONAL DATABASE
Kenneth Gundle
Favorite
(P 223) ASSOCIATION OF POSTOPERATIVE INFECTION (POI) WITH SOFT TISSUE SARCOMA (STS) RESECTION OUTCOMES
Kenneth Gundle
Favorite
(P 285) A NOVEL METHOD TO PREDICT HEIGHT AT SKELETAL MATURITY IN PEDIATRIC SARCOMA PATIENTS
Kenneth Gundle
Favorite
Gunnesson, Lisa

University of Gothenburg/Institute of Clinical Sciences
(P 20) LEIOMYOSARCOMA OF THE THORACIC AORTA - A RARE CASE REPORT
Lisa Gunnesson
Favorite
(P 382) PARAGANGLIOMA AND CONGENITAL HEART DISEASE - A RARE CASE REPORT
Lisa Gunnesson
Favorite
Guo, Hong-fen

Memorial Sloan Kettering Cancer Center
(P 302) HER2 PRETARGETED ALPHA PARTICLE RADIOIMMUNOTHERAPY FOR DESMOPLASTIC SMALL ROUND CELL TUMORS
Hong-fen Guo
Favorite
Guo, Jinhong

Ontada
(P 133) REAL-WORLD ANALYSIS OF DEDIFFERENTIATED LIPOSARCOMA (DDLPS) IN A US COMMUNITY ONCOLOGY SETTING
Jinhong Guo
Favorite
Guo, Qiuxiang

Abbisko Therapeutics Co., Ltd
(P 407) LONG-TERM EFFICACY AND SAFETY PROFILE OF PIMICOTINIB (ABSK021) IN TENOSYNOVIAL GIANT CELL TUMOR (TGCT): PHASE 1B UPDATE.
Qiuxiang Guo
Favorite
Guo, Xi

Department of Medical Oncology, Zhongshan Hospital, Fudan University, Shanghai, China
(P 416) TRIPLR COMNINATION THERAPY IN THE FIRST-LINE TREATMENT OF SOFT TISSUE SARCOMA WITH HIGH TUMOR BURDEN: INTERIM ANALYSIS FROM ALTER-S007 STUDY
Xi Guo
Favorite
guo, Zhen

The First Hospital of Jilin University
(P 119) UPDATED RESULTS OF A SINGLE-ARM,MULTI-CENTER STUDY OF ANLOTINIB COMBINED WITH TORIPALIMAB IN FIRST-LINE TREATMENT OF UNRESECTABLE OR METASTATIC UNDIFFERENTIATED PLEOMORPHIC SARCOMA
Zhen guo
Favorite
Gupta, Abha

Princess Margaret Cancer Centre, Hospital for Sick Children, AYA, CanSaRCC
(P 153) PATTERNS, MANAGEMENT AND SURVIVAL OUTCOMES OF PATIENTS WITH EPITHELIOID HEMANGIOENDOTHELIOMA: A NATIONWIDE ANALYSIS FROM THE CANADIAN SARCOMA RESEARCH AND CLINICAL COLLABORATION DATABASE
Abha Gupta
Favorite
(P 293) CIC-REARRANGED SOFT TISSUE SARCOMAS: DOES CHEMOTHERAPY CHANGE NATURAL HISTORY AND PROGNOSIS? A CANADIAN SARCOMA RESEARCH AND CLINICAL COLLABORATION (CANSARCC) STUDY
Abha Gupta
Favorite
Gupta, Abha

Hospital for Sick Children
(P 304) LOCAL CONTROL FOR PEDIATRIC RHABDOMYOSARCOMA OF THE EXTREMITIES. IS RADIOTHERAPY ALWAYS REQUIRED AFTER ADEQUATE SURGICAL RESECTION?
Abha Gupta
Favorite
(P 315) SALVAGE THERAPY EFFICACY IS MODIFIED BY RISK GROUP AT DIAGNOSIS IN PATIENTS WITH RELAPSED RHABDOMYOSARCOMA
Abha Gupta
Favorite
Gupta, Abha

Princess Margaret Cancer Centre, Hospital for Sick Children, AYA, CanSaRCC
(P 320) WHAT IS THE ROLE OF CHEMOTHERAPY IN PATIENTS (PTS) WITH SPINDLE CELL/SCLEROSING RHABDOMYOSARCOMA (SCRMS): A CANADIAN SARCOMA RESEARCH AND CLINICAL COLLABORATION (CANSARCC) STUDY
Abha Gupta
Favorite
Gupta, Abha

Hospital for Sick Children
(P 321) WHOLE ABDOMINAL RADIOTHERAPY IN CHILDREN AND YOUNG ADULTS WITH SARCOMA: A CANADIAN SARCOMA AND CLINICAL COLLABORATION (CANSARCC) STUDY
Abha Gupta
Favorite
(P 329) DEVELOPING ARMS METASTATIC MODELS TO RECAPITULATE THE TUMOR MICROENVIRONMENTS OF THE AXILLA/LYMPH NODE AND LUNGS
Abha Gupta
Favorite
Gupta, Ajay

Roswell Park Comprehensive Cancer Center
(P 35) EARLY REAL WORLD EXPERIENCE WITH NIROGACESTAT IN PATIENTS WITH DESMOID FIBROMATOSIS
Ajay Gupta
Favorite
Gupta, Karan

Chris O'Brien Lifehouse
(P 157) REAL WORLD CLINICAL UTILITY OF NEXT GENERATION SEQUENCING IN ADOLESCENT AND YOUNG ADULT SARCOMA PATIENTS
Karan Gupta
Favorite
Gupta, Nishith

Narayana Hospital
(P 32) CURRENT INDICATIONS OF OPEN SURGERY IN PRIMARY APPENDICULAR/ PELVIC ANEURYSMAL BONE CYSTS
Nishith Gupta
Favorite
Gupta, Vandana

V Care Foundation
(P 201) GLOBAL CROSS-SECTIONAL SURVEY ON SARCOMA DIAGNOSIS PATHWAY: A CURRENT STATE ANALYSIS
Vandana Gupta
Favorite
Gupta, Varsha

Roswell Park Comprehensive Cancer Center
(P 35) EARLY REAL WORLD EXPERIENCE WITH NIROGACESTAT IN PATIENTS WITH DESMOID FIBROMATOSIS
Varsha Gupta
Favorite
Gurrieri, Lorena

Clinical and Experimental Oncology, Immunotherapy, Rare Cancers and Biological Resource Center, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", 47014 Meldola, Italy
(P 144) EXPLORATORY ANALYSIS OF 68GA-FAPI-46 PET-CT IN SOFT TISSUE SARCOMA
Lorena Gurrieri
Favorite
(P 415) TRABECTEDIN PLUS OLAPARIB IN ADVANCED LEIOMYOSARCOMA PROGRESSING AFTER STANDARD TREATMENTS FOR ADVANCED DISEASE: A POOLED ANALYSIS OF TOMAS AND TOMAS2 STUDIES FROM THE ITALIAN SARCOMA GROUP.
Lorena Gurrieri
Favorite
Guryeva, Valeria

Sarcoma Oncology Center
(P 106) DELTAREX-G, A TUMOR TARGETED CCNG1 INHIBITOR, DEMONSTRATES CLINICAL BENEFIT IN ADVANCED CHEMORESISTANT SARCOMA FOLLOWING FDA CBER AUTHORIZATION FOR USE AS PLATFORM THERAPY WITH FDA APPROVED DRUGS
Valeria Guryeva
Favorite
(P 250) UPDATE ON GALLANT: A PHASE 2 STUDY USING METRONOMIC GEMCITABINE, DOXORUBICIN AND DOCETAXEL PLUS NIVOLUMAB IN PREVIOUSLY TREATED SARCOMA (NCT04535713)
Valeria Guryeva
Favorite
Gustafson, Alexandra

Surgery Branch, NCI, NIH
(P 231) IDENTIFICATION OF NEOANTIGEN FROM PECOMA-LIKE NEOPLASM PROVIDES RATIONALE FOR TREATMENT WITH CELLULAR THERAPY
Alexandra Gustafson
Favorite
Gutiérrez, Natalia

Hospital General Universitario Gregorio Marañón
(P 432) THE ROLE OF SYSTEMIC TREATMENT IN ADVANCED SOLITARY FIBROUS TUMORS: EXPERIENCE AT A REFERRAL CENTER.
Natalia Gutiérrez
Favorite
Gutiérrez, Ana

Medical Oncology Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain
(P 432) THE ROLE OF SYSTEMIC TREATMENT IN ADVANCED SOLITARY FIBROUS TUMORS: EXPERIENCE AT A REFERRAL CENTER.
Ana Gutiérrez
Favorite
Gutierrez, Antonio

HU Son Espases
(P 234) IMMUNOSARC II MASTER TRIAL (PHASE II OF SUNITINIB AND NIVOLUMAB): RESULTS FROM THE CLEAR CELL SARCOMA (CCS) COHORT. A GEIS, ISG, AND UCL STUDY
Antonio Gutierrez
Favorite
Gutierrez, Wade

University of Iowa
(P 12) GENETIC LANDSCAPE OF MPNST DETERMINES METABOLIC STRATEGIES AND THERAPEUTIC OPPORTUNITIES FOR COPING WITH REDOX STRESS
Wade Gutierrez
Favorite
Gutstein, Lauren

Children's Hospital of Philadelphia
(P 318) SYNOVIAL SARCOMA REGISTRY AND BIOSPECIMEN REPOSITORY: DESCRIBING THE COHORT AND SURVIVAL OUTCOMES TO DATE
Lauren Gutstein
Favorite
Gyorki, David

Peter MacCallum Cancer Centre
(P 151) MOLECULAR ANALYSIS OF CUTANEOUS SARCOMATOID NEOPLASMS FREQUENTLY IDENTIFIES MELANOMA DRIVER VARIANTS
David Gyorki
Favorite
(P 390) VARIATIONS IN GLOBAL PATTERNS OF CARE FOR RETROPERITONEAL SARCOMAS - A STUDY BY TARPSWG
David Gyorki
Favorite